Spondylitis News and Research

RSS

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Celecoxib combined with TNF inhibitors was associated with the greatest reduction in radiographic progression.

14 Jun 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

New study launched to examine effects of rheumatologic agent on bone health

Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.

7 May 2018

Online consultation via mobile app reduces costs and delays for rheumatic disease patients

Researchers in China have developed a new online consultation tool for rheumatic disease patients, which may strengthen the interaction between doctors and patients and lead to more efficient management of chronic illness, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.

16 Jun 2017

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug-target binding in a physiological environment and at clinically-relevant concentrations.

15 May 2017

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints®, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy and patient-centered research, today announced the publication of “Raising the Voice of the Patients: A Patient’s Guide to Living with Rheumatoid Arthritis”.

25 Jan 2017

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy, and patient-centered research, today announced the forthcoming publication of “A Patient’s Guide to Living with Rheumatoid Arthritis.”

15 Nov 2016

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

23 Sep 2016

Swimming can be effective option for treating patients with fibromyalgia pain

A study performed by researchers at the Federal University of São Paulo shows swimming is as effective as walking to relieve pain and improve quality of life for patients with fibromyalgia.

19 Aug 2016

Facebook advertising could be more effective way of identifying IBP patients

The results of a UK study presented today at the European League Against Rheumatism Annual Congress showed that busing Facebook to raise awareness about the symptoms of Inflammatory Back Pain (IBP) and the need to seek medical help early may reduce the delay in diagnosis and treatment.

13 Jun 2016

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

10 Jun 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016

Global research links genes to five common, hard-to-treat inflammatory diseases

A global study involving 50 different research centres has found hundreds of genes which cause five common, hard-to-treat and debilitating inflammatory diseases, paving the way to new treatments for these conditions

16 Mar 2016

Novartis announces FDA approval of Cosentyx for treatment of adult patients with AS and PsA

Novartis announced today that the US Food and Drug Administration has approved Cosentyx (secukinumab) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

17 Jan 2016

NEJM publishes results of Cosentyx Phase III studies in ankylosing spondylitis

Novartis announced today that the results of the MEASURE 1 and MEASURE 2 Phase III studies for Cosentyx® (secukinumab) in ankylosing spondylitis (AS) were published in The New England Journal of Medicine (NEJM). These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in reducing the signs and symptoms of active AS – a long-term, painful and debilitating inflammation of the spine.

24 Dec 2015

Genetic information of patients with IBD could provide road map for more effective treatments

Genetic variation in patients with inflammatory bowel disease (IBD) appears to play a major role in determining how sick they will become and could provide a road map for more effective treatments.

1 Dec 2015

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announced today that the European Commission has approved Cosentyx (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor (anti-TNF) therapy.

25 Nov 2015

Novartis’ Cosentyx® show no progression in spinal damage in 80% of ankylosing spondylitis patients

Novartis announced today late-breaking two year results for Cosentyx® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment. This is the first time that data on structural spinal progression in AS have been presented for an interleukin-17A (IL-17A) inhibitor.

9 Nov 2015